Literature DB >> 31399528

Allogeneic hematopoietic stem cell transplantation for primary central nervous system lymphoma.

Thomas Mika1, Swetlana Ladigan1, Alexander Baraniskin1, Deepak Vangala1, Sabine Seidel2, Olaf Hopfer3, Michael Kiehl4, Roland Schroers5.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31399528      PMCID： PMC7109742          DOI： 10.3324/haematol.2019.227199

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  21 in total

Review 1.  Treatment of Primary Central Nervous System Lymphoma: From Chemotherapy to Small Molecules.

Authors:  Joe S Mendez; Christian Grommes
Journal:  Am Soc Clin Oncol Educ Book       Date:  2018-05-23

2.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

3.  High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission.

Authors:  Zachariah DeFilipp; Shuli Li; Areej El-Jawahri; Philippe Armand; Lakshmi Nayak; Nancy Wang; Tracy T Batchelor; Yi-Bin Chen
Journal:  Cancer       Date:  2017-04-03       Impact factor: 6.860

Review 4.  Aspects concerning busulfan pharmacokinetics and bioavailability.

Authors:  M Hassan; H Ehrsson; P Ljungman
Journal:  Leuk Lymphoma       Date:  1996-08

5.  Novel agents for primary central nervous system lymphoma: evidence and perspectives.

Authors:  Gerald Illerhaus; Elisabeth Schorb; Benjamin Kasenda
Journal:  Blood       Date:  2018-07-09       Impact factor: 22.113

6.  High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group.

Authors:  B Kasenda; G Ihorst; R Schroers; A Korfel; I Schmidt-Wolf; G Egerer; L von Baumgarten; A Röth; J Bloehdorn; R Möhle; M Binder; U Keller; M Lamprecht; M Pfreundschuh; E Valk; H Fricker; E Schorb; K Fritsch; J Finke; G Illerhaus
Journal:  Leukemia       Date:  2017-05-31       Impact factor: 11.528

7.  Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma.

Authors:  Jaewon Hyung; Jung Yong Hong; Dok Hyun Yoon; Shin Kim; Jung Sun Park; Chan-Sik Park; Sang-Wook Lee; Jeong Hoon Kim; Jin Sook Ryu; Jooryung Huh; Cheolwon Suh
Journal:  Ann Hematol       Date:  2019-04-15       Impact factor: 3.673

8.  PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma.

Authors:  Lakshmi Nayak; Fabio M Iwamoto; Ann LaCasce; Srinivasan Mukundan; Margaretha G M Roemer; Bjoern Chapuy; Philippe Armand; Scott J Rodig; Margaret A Shipp
Journal:  Blood       Date:  2017-03-29       Impact factor: 22.113

9.  Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study.

Authors:  Caroline Houillier; Luc Taillandier; Sylvain Dureau; Thierry Lamy; Mouna Laadhari; Olivier Chinot; Cecile Moluçon-Chabrot; Pierre Soubeyran; Remy Gressin; Sylvain Choquet; Gandhi Damaj; Antoine Thyss; Julie Abraham; Vincent Delwail; Emmanuel Gyan; Laurence Sanhes; Jérôme Cornillon; Reda Garidi; Alain Delmer; Marie-Laure Tanguy; Ahmad Al Jijakli; Pierre Morel; Pascal Bourquard; Marie-Pierre Moles; Adrien Chauchet; Thomas Gastinne; Jean-Marc Constans; Adriana Langer; Antoine Martin; Patricia Moisson; Lucette Lacomblez; Nadine Martin-Duverneuil; Daniel Delgadillo; Isabelle Turbiez; Loïc Feuvret; Nathalie Cassoux; Valérie Touitou; Damien Ricard; Khê Hoang-Xuan; Carole Soussain
Journal:  J Clin Oncol       Date:  2019-02-20       Impact factor: 44.544

10.  Allogeneic stem cell transplantation for relapsed primary central nervous system lymphoma: Is it feasible?

Authors:  Erden Atilla; Ugur Sahin; Pinar Ataca Atilla; Mustafa Merter; Elif Ozyurek; Koray Ceyhan; Sinem Civriz Bozdag
Journal:  Hematol Oncol Stem Cell Ther       Date:  2018-03-16
View more
  4 in total

1.  High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation in Relapsed or Refractory Primary CNS Lymphoma: A Retrospective Monocentric Analysis of Long-Term Outcome, Prognostic Factors, and Toxicity.

Authors:  Sabine Seidel; Verena Nilius-Eliliwi; Thomas Kowalski; Deepak Ben Vangala; Uwe Schlegel; Roland Schroers
Journal:  Cancers (Basel)       Date:  2022-04-23       Impact factor: 6.575

2.  Relapsed and refractory primary CNS lymphoma: treatment approaches in routine practice.

Authors:  Prakash Ambady; Nancy D Doolittle; Christopher P Fox
Journal:  Ann Lymphoma       Date:  2021-09

3.  Treatment of leptomeningeal disease in blastic plasmacytoid dendritic cell neoplasm following tagraxofusp-erzs induction.

Authors:  Deepak B Vangala; Verena Nilius-Eliliwi; Thomas Mika; Thilo Gambichler; Rene Stranzenbach; Roland Schroers
Journal:  Haematologica       Date:  2022-08-01       Impact factor: 11.047

4.  Systemic Relapse in a Young Adult Patient with Primary CNS Diffuse Large B-Cell Lymphoma.

Authors:  Adam Khorasanchi; Zachary Benson; Misty Hall; Nelya Ebadirad; Mohammad H Gharavi; Patrick Willard; Miranda Chimzar; John McKay; Gary Simmons; Victor Yazbeck
Journal:  Case Rep Hematol       Date:  2022-06-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.